Parnate

Mental Depression

Treatment

2 FDA approvals

2 Active Studies for Parnate

What is Parnate

Tranylcypromine

The Generic name of this drug

Treatment Summary

Tranylcypromine is an antidepressant medication used to treat major depression, dysthymic disorder, atypical depression, panic attacks, and phobic disorders. It is a type of monoamine oxidase inhibitor (MAOI) formed from the cyclization of the side chain of amphetamine. Tranylcypromine works by blocking monoamine oxidase, an enzyme that breaks down serotonin, norepinephrine, and dopamine in the brain.

Parnate

is the brand name

image of different drug pills on a surface

Parnate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Parnate

Tranylcypromine

1989

17

Approved as Treatment by the FDA

Tranylcypromine, also known as Parnate, is approved by the FDA for 2 uses which include Acute Depressive Episode and Mental Depression .

Acute Depressive Episode

Mental Depression

Effectiveness

How Parnate Affects Patients

Tranylcypromine is a type of antidepressant that works by increasing the levels of certain chemicals (serotonin, norepinephrine, epinephrine, and dopamine) in the brain. It belongs to a group of drugs called monoamine oxidase inhibitors (MAOIs) and is thought to be effective because it increases the amount of these chemicals that are available for the brain to use. It is not clear how it works, but it is believed to be more effective than selective MAO B inhibitors, such as selegiline, which do not have antidepressant effects.

How Parnate works in the body

Tranylcypromine works by blocking the enzyme monoamine oxidase (MAO). This enzyme helps regulate the amount of certain chemicals, such as monoamines, released in the brain. Low levels of these chemicals are associated with depression, so by blocking MAO, Tranylcypromine helps to increase the levels of these chemicals in the brain, easing depression symptoms.

When to interrupt dosage

The recommended amount of Parnate is contingent upon the diagnosed ailment. The dosage fluctuates depending on the technique of delivery (e.g. Tablet, film coated - Oral or Tablet - Oral) as noted in the table below.

Condition

Dosage

Administration

Mental Depression

, 10.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Parnate Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pheochromocytoma

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

consumption of cheese

Do Not Combine

Pulse Frequency

Do Not Combine

cerebrovascular defects

Do Not Combine

Pulse Frequency

Do Not Combine

Elective Surgeries

Do Not Combine

Pulse Frequency

Do Not Combine

consumption of high tyramine diet

Do Not Combine

Pulse Frequency

Do Not Combine

Cardiovascular Diseases

Do Not Combine

There are 20 known major drug interactions with Parnate.

Common Parnate Drug Interactions

Drug Name

Risk Level

Description

2,5-Dimethoxy-4-ethylamphetamine

Major

Tranylcypromine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

Tranylcypromine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylthioamphetamine.

4-Bromo-2,5-dimethoxyamphetamine

Major

Tranylcypromine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.

5-methoxy-N,N-dimethyltryptamine

Major

The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Tranylcypromine.

7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline

Major

The risk or severity of adverse effects can be increased when Tranylcypromine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.

Parnate Toxicity & Overdose Risk

An overdose of this drug can cause sleeplessness, agitation, confusion, dizziness, weakness, and drowsiness. In some cases, blood pressure may either increase or decrease, along with severe headaches. Rarely, increased blood pressure is accompanied by muscle twitching, high body temperature, and ultimately leading to a rigid body and loss of consciousness.

image of a doctor in a lab doing drug, clinical research

Parnate Novel Uses: Which Conditions Have a Clinical Trial Featuring Parnate?

Five ongoing clinical trials are investigating the potential of Parnate to alleviate Mental Depression.

Condition

Clinical Trials

Trial Phases

Mental Depression

2 Actively Recruiting

Phase 2, Not Applicable

Parnate Reviews: What are patients saying about Parnate?

5

Patient Review

12/12/2015

Parnate for Major Depressive Disorder

Parnate was suggested to me by my doctor after trying a lot of different medications and ECT treatments, and it honestly changed my life. I went from being suicidal and cutting myself regularly to feeling happy and content. There are some diet restrictions that come with this medication, but they're definitely worth it in the long run.

5

Patient Review

11/3/2021

Parnate for Depression

Parnate has been a life-saver for me. It's controlled my depression and anxiety better than any of the other 20+ drugs and drug combinations I've tried. And while I do have to be careful with my diet, it's a small price to pay for how well this medication works.

5

Patient Review

11/6/2021

Parnate for Depression

Parnate has been an absolute wonder drug for me. I had tried so many different combinations of drugs and nothing seemed to work until I found this one. It's really helped me stabilize my mental health.

5

Patient Review

1/17/2014

Parnate for Depression

I've been taking this medicine for over 35 years and it's the only thing that's ever helped me. I've tried many other treatments, but this is the only one that's worked.

5

Patient Review

1/15/2014

Parnate for Major Depressive Disorder

I've used this treatment for 30 years and it always helps.

4.7

Patient Review

1/7/2021

Parnate for Depression

If you haven't tried a classical MAOI for depression, then this drug is definitely worth considering. It's much more effective than anything else on the market, with powerful antidepressant and anxiolytic effects. That said, the side effects can be pretty annoying (especially insomnia and afternoon fatigue).

3.7

Patient Review

3/21/2014

Parnate for Major Depressive Disorder

Parnate has been great for my depression, however I have gained over 100 pounds since taking it. This is a common side effect that unfortunately makes the drug unusable for me.

2.7

Patient Review

6/12/2022

Parnate for Major Depressive Disorder

I'm only a month in on this treatment, and I've already got so many questions. I started at 10mg and slowly increased to 20mg over the course of 3 1/2 weeks. It's helped with my depression, but the side effects are really intense. Dizziness, shortness of breath, anxiety, muscle pain, and neck pain have all been issues. If anyone else has experienced even some of these problems, please let me know in the comments!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about parnate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Parnate a stimulant?

"Parnate has stimulating effects at normal doses because it affects the neurotransmitter norepinephrine. At high doses, Parnate can cause a "buzz" similar to the effects of amphetamines or other stimulants."

Answered by AI

What type of antidepressant is Parnate?

"An antidepressant that is also an MAO inhibitor."

Answered by AI

Is Parnate good for anxiety?

"Tranylcypromine, another MAOI, may be effective against panic attacks. Its possible benefits include reducing panic attacks, elevating depressed mood, increasing confidence, and helping OCD, generalized anxiety, PTSD and social anxiety."

Answered by AI

What does the drug Parnate do?

"This text is discussing how tranylcypromine is used to treat depression by restoring the balance of neurotransmitters in the brain. It states that usually this medication is used in persons who have not responded to other drugs."

Answered by AI

Clinical Trials for Parnate

Image of The Royal's Institute of Mental Health Research in Ottawa, Canada.

fMRI-Guided rTMS for Depression

18+
All Sexes
Ottawa, Canada

In this triple-blind randomized controlled trial, we ask if targeting intermittent theta burst stimulation (iTBS) based on individual resting state connectivity improves treatment outcomes in major depressive disorder (MDD). For the trial, we will recruit 210 patients with major depressive disorder. Each patient will undergo a 30-40-minute MRI scan, after which they will receive a 6-week standard iTBS treatment. Participants will be randomized to receive iTBS either to the standard neuronavigated target (a technique for treatment location targeting, based on group-average connectivity) or to a personalized connectivity-guided target selected based on individual functional connectivity scans. The main outcome of this trial is response rate as determined by ≥ 50% reduction in Grid HRSD-17 scores. Secondary outcomes include remission rate, change in depression, anxiety and anhedonia symptoms, quality of life, and biological measures of heart rate variability, objective sleep measures and daily activity as a proxy of anhedonia - defined as a reduced ability to experience pleasure.

Recruiting
Has No Placebo

The Royal's Institute of Mental Health Research

Sara Tremblay, PhD

Image of The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital in Boston, United States.

Bezafibrate for Bipolar Disorder

18 - 65
All Sexes
Boston, MA

We propose to test the hypothesis that bezafibrate, a pan-PPAR agonist, may be effective and safe for bipolar depression with the following specific aims: Aim #1. Proof-of-Concept Safety and Tolerability Aim: To assess the safety and tolerability of bezafibrate added to anti-manic medication for bipolar depression, especially with regard to worsening manic symptoms and suicidal ideation. We will conduct a phase IIa, 8-week, open pilot trial of bezafibrate added to FDA-approved anti-manic medication in 30 participants with bipolar depression. We will monitor changes in manic symptoms (Young Mania Rating Scale), suicidal ideation, cognitive functioning specifically in attention and verbal memory, and treatment emergent adverse events (SAFTEE). We will also monitor changes in the Framingham Cardiovascular Risk Score. Aim #2. Preliminary Assessment of Efficacy: To assess the antidepressant efficacy of bezafibrate added to anti-manic medication for acute bipolar I major depressive episodes. Hypothesis: The bezafibrate group will have a statistically significant decrease in the Montgomery Asberg Rating Scale (MADRS) Scores over 8 weeks. The results of this proof-of concept phase IIa study will help us to plan a placebo-controlled randomized trial. In summary, we propose an 8-week, proof-of-concept open pilot trial of an adjunctive pan-PPAR agonist, bezafibrate, for 30 patients with an acute bipolar I major depressive episode. The study may have a profound impact on the development of a novel treatment consistent with the mitochondrial dysregulation hypothesis of bipolar disorder and, to the best of our knowledge, will be the first proof-of-concept trial to assess a pan-PPAR agonist for bipolar disorder.

Phase 2
Recruiting

The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital

Andrew A. Nierenberg, M.D.